Skip to main content
AIBT
OTC Life Sciences

AIBiotics Q3 10-Q: Going Concern Reaffirmed, Material Weakness Disclosed, Share Count Tops 1 Billion

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Technology
Sentiment info
Negative
Importance info
8
Price
$0.003
Mkt Cap
$2.581M
52W Low
$0
52W High
$0.017
52W Position info
867% above low
Off High info
83% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

AIBT has more than doubled off its 52-week low of $0 on light trading volume (0.3× avg).

Summary

AIBiotics' Q3 2026 10-Q shows a $1.24 million nine-month net loss, $223,074 of cash against $5.17 million of current liabilities, a reaffirmed going concern warning, a newly disclosed material weakness, and a share count that has passed 1 billion through debt-to-equity conversions.


Key Events · Earnings and Guidance · AIBT

  • Going Concern Doubt Reaffirmed

    Management states substantial doubt about the ability to continue as a going concern, citing a $4,906,285 working capital deficit at September 30, 2026 ($265,266 current assets vs $5,171,551 current liabilities).

  • Material Weakness Disclosed

    The CEO/Principal Accounting Officer concluded disclosure controls and procedures were not effective at September 30, 2026 as a result of a material weakness in internal control over financial reporting.

  • Dilution From Debt Conversions

    167,658,700 shares were issued in Q3 2026, including 129,712,083 on conversion of $104,880 principal and $18,071 accrued interest at $0.0005 per share; shares outstanding rose to 890,165,334 from 486,895,359 at December 31, 2025.

  • Post-Quarter Share Count Hits 1 Billion

    On October 29, 2026 the company issued 10,000,000 shares to director Mark Croskery and 100,000,000 shares to CEO Ben Kaplan for accrued compensation, bringing shares outstanding to 1,000,165,334 as of November 19, 2026; $823,000 of Kaplan's compensation remains unpaid.


Analysis · AIBT · Life Sciences

Cash of $223,074 against $5.17 million of current liabilities leaves a $4.9 million working capital hole, and management again flags substantial doubt about the company's ability to continue as a going concern. The only funding mechanism on display is converting debt and accrued payables into stock at fractions of a cent: 167.7 million shares were issued in Q3 2026 alone, and the count has since grown to 1,000,165,334 after 110 million shares went to the CEO and a director for unpaid compensation. A material weakness in internal control over financial reporting is also disclosed, meaning disclosure controls were not effective. On top of an already deeply negative equity position of $4.8 million, the pending Empulser acquisition (up to $22 million in Series C preferred, 90% milestone-contingent) and the NovaCore asset deal add future share obligations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AIBT was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.00 to $0.02. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIBT - Latest Insights

AIBT
Oct 16, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0021
Real-time Price: $0.0029 info
Change: +$0.0008 (+38%) info
Market Cap: $2.581M info
AIBT
Oct 02, 2026, 6:50 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0022
Real-time Price: $0.0029 info
Change: +$0.0007 (+32%) info
Market Cap: $2.581M info
AIBT
Aug 19, 2026, 5:25 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.0004
Real-time Price: $0.0029 info
Change: +$0.0025 (+625%) info
Market Cap: $2.581M info
AIBT
Jun 09, 2026, 6:11 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.0009
Real-time Price: $0.0029 info
Change: +$0.0020 (+222%) info
Market Cap: $2.581M info
AIBT
Jun 08, 2026, 7:12 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.0009
Real-time Price: $0.0029 info
Change: +$0.0020 (+222%) info
Market Cap: $2.581M info